Delivery Order SPE2DB24D2101-SPE2DB25FKNQA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,196.02 to AmerisourceBergen Drug Corp for 4,568,895,450 units of Actemra 400 mg/20 mL vials on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract utilizes firm fixed pricing with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,295.36 to AmerisourceBergen Drug Corp for the supply of ACTEMRA 200 mg/10 mL vials. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9M through December 2026. The delivery order was awarded on July 30, 2025, with a completion date of July 31, 2025, and will be performed at...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 12, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $4,594.53. This firm fixed-price, competitively awarded delivery order is funded by the Defense Logistics Agency's Medical Supply Chain, a defense-focused federal agency, and has an ultimate completion date of August 13, 2025. The award was made under no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Actemra 400 mg/20 mL vials with a ceiling value of $6,595.84. This non-set-aside contract award was competitively procured on a firm fixed-price basis, with an ultimate completion date of August 19, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a delivery order valued at $3,328.29 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Actemra 162 mg/0.9 ml syringes. This firm fixed-price delivery order is scheduled for completion by July 31, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,571.72 firm fixed price delivery order contract, awarded on October 16, 2024, is for the supply of ACTEMRA 400 MG/20 ML VIAL 20ML, a specialty medication. The contract has an ultimate completion date of October 17, 2024 and was not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,490.23, is a delivery order for the pharmaceutical product ACTEMRA 400 MG/20 ML VIAL 20ML. The contract has an ultimate completion date of April 14, 2025 and is a firm fixed price contract. AmerisourceBergen has established itself as a key vendor for federal healthcare programs, particularly...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Actemra 400 mg/20 mL vials with a ceiling value of $2,798.77 and a firm fixed price structure. This delivery order represents a pediatric quantity of the pharmaceutical product and is expected to be completed by August 14, 2025. The contract utilized no set-aside designation, indicating competitive award procedures, and will be performed at AmerisourceBergen's corporate...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,066.95 by the Defense Logistics Agency (DLA) on July 24, 2025, with ultimate completion scheduled for July 25, 2025. The contract covers the supply of Actemra ActPen 162 mg/0.9 mL injections and was awarded through competitive bidding without set-aside designation under a firm fixed-price arrangement. This delivery order operates as a child...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKNQADelivery Order
The Defense Logistics Agency awarded a $14.3K delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Actemra 200 mg/10 ml vials. This competitively awarded, firm fixed-price contract is scheduled for completion by August 19, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $1 billion ceiling through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, maintains a significant federal contracting portfolio focused on supplying medications, vaccines, and medical supplies to Defense Health Agency customers, the U.S. Coast Guard, and other government healthcare systems. As a critical vendor in the federal medical procurement supply chain, the company regularly fulfills delivery orders for brand-name and generic pharmaceuticals across multiple therapeutic domains. This particular award reflects the company's ongoing role in supporting military medical logistics through DLA's pharmaceutical supply network, with no set-aside designation applied.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.3k | 8/18/25 |